• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    汉

    汉密尔顿手表公司

    Hamilton Watch Company
    企业
    969论文总数
    1.2万引用总数

    The Hamilton Watch Company is a Swiss manufacturer of wristwatches based in Bienne, Switzerland. The Hamilton Watch Company had its genesis as an American watch design and manufacturing company, which incorporated in 1892 and produced its first watch in 1893. After its formation, the Hamilton Watch Company went on to manufacture and market pocket watches and wristwatches, ending American manufacture in 1969. Through a series of mergers and acquisitions, the Hamilton Watch Company became a diversified conglomerate itself and was subsequently integrated into the Swatch Group. Today the brand is one of more than twenty watch brands belonging to the Swatch Group, the world's largest watch manufacturer and marketer.

    论文量&引用量时间轴

    机构学者

    论文(969)

    年份
    起
    –
    止
    排序
    1The Minimum Frequency of Well-day Capillary Blood Ketone Testing Needed to Predict Near-Term Diabetic Ketoacidosis (DKA) in Type 1 Diabetes
    YUCHENG ZHANG,DALTON BUDHRAM,PRIYA BAPAT,SHARON DHALIWAL,ETHAN PARIKH,HODA GAD, WAJEEHA CHEEMA,ABDULMOHSEN BAKHSH,NATASHA VERHOEFF,ALANNA WEISMAN,DAVID CHERNEY,LEIF ERIK LOVBLOM,
    2026Canadian Journal of Diabetes(2026)
    引用
    AI阅读
    加入学术空间
    2Patient-held Tools Supporting Gestational Diabetes Mellitus Care Across the Perinatal Continuum: A Scoping Review
    AIMEN ZEHRA,KATELYN SUSHKO,DIANA SHERIFALI,LORRAINE LIPSCOMBE
    2026Canadian Journal of Diabetes(2026)
    引用
    AI阅读
    加入学术空间
    3Comparison of Intensive Versus Conventional Glycemic Control Targets: an Updated Systematic Review and Meta-Analysis of the 2024 Society of Critical Care Medicine Guidelines on Glycemic Control for Critically Ill Adults
    Michael Sirimaturos,Kimia Honarmand,Micah T Long, Jean-Charles Preiser,A Dave Nagpal,Michael S D Agus, Janan Aldouhan,Nicholas G Bircher, David L Carpenter, Karin Dearness, Elizabeth A Farrington,Amado X Freire,

    OBJECTIVES:To perform an updated systematic review and meta-analysis of the efficacy and safety of intensive (INT) vs. conventional (CONV) blood glucose (BG) targets for critically ill adults on insulin infusions. DATA SOURCES:We conducted a comprehensive search of Embase and OVID Medline databases from inception to October 16, 2023. We manually excluded studies published before 2000 due to potential lack of relevance as glycemic control in the ICU was not routinely practiced before 2000. STUDY SELECTION:We included randomized controlled trials (RCTs) evaluating adult, critically ill patients on insulin infusions comparing INT vs. CONV targets for efficacy and safety outcomes. DATA EXTRACTION:Data were screened and extracted with accuracy confirmed by a second reviewer. Study methodological characteristics, patient population, interventions, and outcome data were recorded. Studies without numerical outcomes were summarized as text statements. DATA SYNTHESIS:Forty-five RCTs were included involving 32,215 patients. No differences were seen between INT and CONV targets for hospital mortality or ICU mortality. INT targets were associated with lower ICU length of stay (LOS), infections, and critical illness polyneuropathy (CIP); however, INT targets demonstrated a 3.6-fold higher risk of severe hypoglycemia. Most of the studies with significant differences contained serious inconsistencies or risk of bias. In the subgroup analyses, INT targets demonstrated favorable neurologic outcomes in neurologic ICU patients, lower ICU LOS in mixed ICU patients, and lower ICU mortality in the cardiac surgery subgroup. CONCLUSIONS:INT BG targets demonstrated mild to moderate improvements in several important morbidity secondary outcomes, including LOS, infections, and CIP, but were associated with a 3.6-fold higher risk of severe hypoglycemia. No differences were seen in ICU or hospital mortality. INT targets should not be routinely used over CONV targets when trying to minimize hypoglycemia as a marker of patient safety. However, as stated in the Society of Critical Care Medicine guidelines, a lower target within the INT range (110-140 mg/dL; 6.1-7.8 mmol/L) may be considered acceptable in select centers where the risk of hypoglycemia is documented to be negligible based on routine assessment and with the use of optimized glycemic management protocols.

    2026Critical care medicine(2026)
    引用
    AI阅读
    加入学术空间
    4CAN WE MEASURE WHAT MATTERS? ANGIOEDEMA OUTCOME REPORTING ACROSS CHRONIC SPONTANEOUS URTICARIA RANDOMIZED CONTROL TRIALS
    V. Lafrance, M. Moskalyk, E. Akomolafe, A. Martins-Ezeifeaku, M. Abu-Hilal

    Introduction Chronic spontaneous urticaria (CSU) manifests as hives and/or angioedema lasting ≥6 weeks. Angioedema impacts up to 50% of CSU patients and is associated with complicated management and impaired quality of life. While biologics omalizumab, dupilumab, and oral therapy remibrutinib are approved for CSU treatment, their effects on angioedema remain poorly defined due to inconsistent outcome reporting. This study evaluates angioedema outcomes and reporting gaps across omalizumab, dupilumab, and remibrutinib randomized controlled trials (RCTs). Methods The systematic review (PROSPERO ID: 1218704) was conducted according to PRISMA guidelines. Web of Science, Medline, Embase, and CENTRAL were searched for January 2012 to November 2025 publications. Eligible trials included phase II/III RCTs, human patients, and reported angioedema outcomes. Risk of bias and certainty of evidence were assessed using RoB2 and GRADE. Random-effects meta-analyses were performed. Results Thirteen phase II/III RCTs were included, and angioedema outcome reporting was highly heterogeneous. Baseline AAS7 was reported in 8/13 trials (61.5%), while AE-QoL and AAS7 week 24 were each reported in 1/13 (7.7%). Angioedema-free days and cumulative angioedema-free weeks were reported in 3/13 (23.1%) and 5/13 (38.5%), respectively, and time to recurrence in 4/13 (30.8%).Meta-analysis of three omalizumab trials demonstrated no significant improvement in angioedema-free days (weeks 4-12) versus placebo [300mg:MD=2.60(95%CI:-0.88-6.08);I²=0%], while pooled-dose sensitivity analysis showed significant benefit [pooled:MD=3.36(95%CI:0.36-6.37);I²=0%]. Conclusion Despite growing CSU therapy availability, their true impact on angioedema remains unclear. Angioedema outcome reporting is inconsistent and unstandardized across RCTs, limiting cross-trial comparability. In future trials, standardized and validated angioedema outcome reporting would enable robust characterization, enhancing widespread patient-centered care.

    2026Annals of Allergy, Asthma & Immunology(2026)
    引用
    AI阅读
    加入学术空间
    5Development of an Implementation Strategy for Patient Partner and Researcher Involvement and Engagement in Research (INSPIRE) Tool: A Focused Mapping Review and Synthesis
    LAURE PERRIER,ISABELLA HERRINGTON,JULIE MAKARSKI,AUNIMA BHUIYA, REBECCA GANNAN, DANA GREENBERG, TRACY MCQUIRE,MONIKA KASTNER
    2026Canadian Journal of Diabetes(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 969 篇论文

    合作机构(100)

    美国国家航空航天局合作论文 23
    华盛顿州立大学温哥华校区合作论文 22
    麦克马斯特大学合作论文 18
    WB Games Montréal合作论文 13
    哈利法克斯银行合作论文 7
    伦敦安大略西部大学合作论文 7
    波音合作论文 5
    Hamilton General Hospital,Hamilton Health Sciences合作论文 4
    Strategic Analysis (United States)合作论文 4
    Jacobs Engineering Group合作论文 4

    机构统计